A senior official in the Central government, during a Secretary-level meeting over the COVID-19 situation in the country on Monday, expressed apprehension that the ongoing Kumbh might become a super spreader , according to a top source in the government. The source said the government is worried about the Kumbh and discussed this at a high-level meeting on Monday. If the government does not decide to end Kumbh before the stipulated time, it may become a COVID-19 super spreader , a member in the high-level meeting said. The government is forming a team that will appeal to all with the help of sadhus and religious leaders to ensure pilgrims, who are visiting the Kumbh, wear masks and follow social distancing, the source told ANI.
Australia and New Zealand agree on a travel bubble starting April 19 Australia and New Zealand have agreed on a comprehensive quarantine-free travel bubble for the first time since the pandemic began last year. Australia’s border has been mostly open to New Zealanders since October, with a few short suspensions when there were small coronavirus outbreaks in Auckland. But until today’s announcement, New Zealand had delayed returning the favour due to more frequent Covid-19 clusters across Australia. The bubble, which will open just before midnight on April 19, is expected to deliver a boost to tourism and to families that have been separated as both countries enacted strict border closures and lockdown measures. Read more
Nearly 97,000 fresh cases reported India reported 96,982 fresh coronavirus infections on Tuesday, taking the cumulative caseload to 1,26,86,049, according to a report in the Scroll. The country saw 446 deaths due to the pandemic, taking the death toll to 1,65,547, according to central health ministry data. The active caseload is at 7,88,223, while the total recoveries have surged to 1,17,32,279. As many as 83.1 million shots have been administered since the nationwide inoculation programme kicked off on January 16. Of these, 43,00,966 were given on Monday. Read more here
Centre assessing stock of remdesivir amid Covid surge Amid a surge in Covid-19 cases, the central government has begun to assess the availability of remdesivir, an antiviral drug, a report in ThePrint said. Remdesivir is a highly sought-after experimental drug to treat Covid-19 patients. The Department of Pharmaceuticals (DoP) has kicked off the drive to check available stocks in states which are reporting high
Your Email:
Send me a copy:
https://mybs.in/2ZdWfAO
India on Monday reported a net increase of 50,233 in active coronavirus cases, the biggest in a day so far, to take its count to 741,830. That is nearly 73 per cent of the September 18 peak of 1,017,754. India’s share of global active coronavirus cases now stands at 3.25 per cent (one in 31). The country is 5
th among the most affected countries by active cases. On Monday, it added 103,558 cases in the biggest single-day jump so far, to take its total caseload to 12,589,067. And, with 478 new fatalities, its Covid-19 death toll reached 165,101, or 1.31 per cent of total confirmed infections.
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.